During the past cycle, following consultation with our internal and external advisory boards, organizational governance structure and the leadership of NCRR, we have focused our efforts on two overarching themes - Translational Therapeutics and Bridging the Pediatric to Adult Divide, taking advantage of resources particular to our institutions. We have fostered interdisciplinary and translational research by a series of """"""""top down"""""""" and """"""""bottom up"""""""" funding initiatives. CTSA support and institutional investment aided by ARRA funding has increased dramatically the footprint of ITMAT more than 7 fold to ~150,000 nsf comprising an expanded, integrated and re-purposed Clinical and Translational Research Center (CTRC) that succeeds the Penn and CHOP GCRCs, dry and wet bench laboratory space, a series of cores and a new home for ITMAT educational programs. ITMAT also supports seminars, workshops and an annual international meeting highlighting the opportunities that the CTSA affords on our campus to pursue clinical and translational research. Interdisciplinary research has increased dramatically on, between, and within the partner institutions during the past funding cycle and these trends have been most pronounced amongst members of ITMAT. During the coming cycle we envisage the continued growth and development of our educational programs;the continued expansion - via recruitment and education - of the critical mass of investigators pursuant of clinical and translational research;enhancement and expansion of our core infrastructure and the development and expansion of programs focused on our two overarching themes. In particular we hope to impact patient care in the community by projecting our two strategic goals to alter the current paradigm of comparative effectiveness research by integrating expertise in basic, pediatric and adult pharmacology and to contribute to predictive strategies in the personalization of medicine.

Public Health Relevance

(provided by applicant): PENN, CHOP, Monell, Wistar Institute, and the University of the Sciences of Philadelphia have benefited greatly from the first cycle of funding of the CTSA, which allowed the development of new centers, research programs, cores and a robust educational program which involve more than 800 investigators across campus and from partner institutions, as well as adding to consortial activities nationally.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR000003-09
Application #
8716825
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Wilde, David B
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
$9,885,102
Indirect Cost
$2,562,395
Name
University of Pennsylvania
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Avitabile, Catherine M; Goldberg, David J; Leonard, Mary B et al. (2018) Leg lean mass correlates with exercise systemic output in young Fontan patients. Heart 104:680-684
Rickels, Michael R; Peleckis, Amy J; Dalton-Bakes, Cornelia et al. (2018) Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes. J Clin Endocrinol Metab 103:105-114
Rickels, M R; Markmann, E; Naji, A (2018) Successful pregnancies after islet transplantation for type 1 diabetes. Am J Transplant :
Wu, Hui-Chen; Do, Catherine; Andrulis, Irene L et al. (2018) Breast cancer family history and allele-specific DNA methylation in the legacy girls study. Epigenetics 13:240-250
Loro, Emanuele; Bisetto, Sara; Khurana, Tejvir S (2018) Mitochondrial ultrastructural adaptations in fast muscles of mice lacking IL15RA. J Cell Sci 131:
Kim, Eun Ji; Grant, Gregory R; Bowman, Anita S et al. (2018) Complete Transcriptome Profiling of Normal and Age-Related Macular Degeneration Eye Tissues Reveals Dysregulation of Anti-Sense Transcription. Sci Rep 8:3040
Beddhu, Srinivasan; Greene, Tom; Boucher, Robert et al. (2018) Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 6:555-563
Beddhu, Srinivasan; Chertow, Glenn M; Cheung, Alfred K et al. (2018) Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation 137:134-143
Bundy, Joshua D; Bazzano, Lydia A; Xie, Dawei et al. (2018) Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol 13:993-1001
Dougherty, Kelly A; Bertolaso, Chiara; Schall, Joan I et al. (2018) Muscle Strength, Power, and Torque Deficits in Children With Type SS Sickle Cell Disease. J Pediatr Hematol Oncol 40:348-354

Showing the most recent 10 out of 515 publications